Advanced Ovarian Cancer (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 32
Special Issue Editor
2. Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan 320315, Taiwan
3. Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, Taipei 100226, Taiwan
Interests: gynecologic cancer; intraperitoneal chemotherapy; sentinel lymph node mapping; hyperthermic intraperitoneal chemotherapy; intraoperative radiotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the past decade, there has been significant progress in the evaluation and treatment of advanced ovarian cancer in addition to a combination of debulking surgery and systemic chemotherapy, such as homologous recombination deficiency evaluation, hyperthermic intraperitoneal chemotherapy, anti-vascular endothelial growth factor therapy, poly ADP-ribose polymerase inhibitor, and even immune checkpoint inhibitor. However, the prognosis of a significant portion of patients with advanced ovarian cancer remains poor. Thus, intensive study is needed to determine the optimal evaluation and treatment strategies.
We welcome submissions in advanced or recurrent ovarian cancer that cover any relevant topic in the areas of risk assessment and stratification, and medical and surgical management strategies.
Prof. Sheng-Mou Hsiao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- advanced ovarian cancer
- medical treatment
- surgical treatment
- hyperthermic intraperitoneal chemotherapy
- intraperitoneal chemotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
